A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

Clinical trial NCT06859762 · RECRUITING

Trial details

NCT number: NCT06859762
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor

Start date: 2025-07-02
Primary completion: 2027-07-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.